SEC Comment Letter 0000000000-24-000003 to Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430) (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430)
Date: Jan. 2, 2024 · CIK: 0001730430 · Accession: 0000000000-24-000003
AI Filing Summary & Sentiment
File numbers found in text: 001-38492
Letter
United States securities and exchange commission logo January 2, 2024 Mark Ragosa Senior Vice President and Chief Financial Officer Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda Re:Kiniksa Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 2, 2023 File No. 001-38492 Dear Mark Ragosa: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Maddy Zeylikman
Show Raw Text
United States securities and exchange commission logo
January 2, 2024
Mark Ragosa
Senior Vice President and Chief Financial Officer
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM11, Bermuda
Re:Kiniksa Pharmaceuticals, Ltd.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 2, 2023
File No. 001-38492
Dear Mark Ragosa:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Maddy Zeylikman